A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

NCT00927082 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

383

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: peginterferon alfa-2a [Pegasys]

Sponsor

Hoffmann-La Roche